Odanacatib

Odanacatib
Odanacatib
Systematic (IUPAC) name
N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide
Clinical data
Pregnancy cat.  ?
Legal status  ?
Routes oral
Identifiers
CAS number 603139-19-1 YesY
ATC code None
PubChem CID 10152654
UNII N673F6W2VH YesY
ChEMBL CHEMBL481611 N
Synonyms (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide
Chemical data
Formula C25H27F4N3O3S 
Mol. mass 525.56 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis[1]. It is an inhibitor of cathepsin K,[2] an enzyme involved in bone resorption.

It is being developed by Merck & Co. As of November 2009, Merck is conducting phase III clinical trials.

References

  1. ^ Le Gall, C. L.; Bonnelye, E.; Clézardin, P. (2008). "Cathepsin K inhibitors as treatment of bone metastasis". Current Opinion in Supportive and Palliative Care 2 (3): 218. doi:10.1097/SPC.0b013e32830baea9. PMID 18685424.  edit
  2. ^ Gauthier JY, Chauret N, Cromlish W, et al. (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. doi:10.1016/j.bmcl.2007.12.047. PMID 18226527. 
v · d · eDrugs for treatment of bone diseases (M05)
Bisphosphonates
Bone morphogenetic proteins
Dibotermin alfa • Eptotermin alfa
Other
Resorption inhibitor (Ipriflavone) • Aluminium chlorohydrate • Dual action bone agent (Strontium ranelate) •
RANKL inhibitor (Denosumab) • Cathepsin K inhibitor (Odanacatib)

M: BON/CAR

anat(c/f/k/f, u, t/p, l)/phys/devp/cell

noco/cong/tumr, sysi/epon, injr

proc, drug(M5)


Stub icon This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.